

REMARKS

The above amendments have been made to place the application in proper form for examination.

The specification has been amended by inserting, as the first paragraph following the title, a sentence updating the status of this application as a divisional of US Patent Application No. 09/886,269, filed June 21, 2001, which claims benefit of US Provisional Application No. 60/217,769, filed July 12, 2000, and claims benefit of US Provisional Application No. 60/291,100, filed May 16, 2001

Claims 1 through 16 have been cancelled since they were allowed in parent application 09/886,269.

Other claims have been amended to incorporate values and text from claims which have otherwise been cancelled. For example, claim 17 has been amended to make it independent by incorporating therein variable values from claim 1. The values R^a-R^e from claims 1 and 11 have been implemented as text where required.

Some typographical errors have been corrected as well. For example, The dependency of claims 42-45 has been changed from claim 39 to claim 41 as the correction of an obvious typographical error.

Multiple dependencies have been eliminated.

It is respectfully submitted that no new matter has been entered

Claims To Priority

Priority claims, both domestic and foreign, are hereby made to all applications in the lineage of this application.

The priority of US Parent Application No. 09/886,269 is claimed under 35 USC §120.

The priority of US provisional application 60/217,769 filed July 12, 2000 and of 60/291,100 filed May 16, 2001 is claimed under 35 USC 119(e).


The priority of foreign application GB 0015472.4 filed June 22, 2000 and of GB 0105857.7 filed March 9, 2001 is claimed under 35 USC §119.

An early and favorable action is respectfully requested.

Respectfully submitted,

Dated: Nov. 25, 2003

Pfizer Inc.
Eastern Point Road
Groton, CT 06340
(860) 441-4903


James T. Jones
Attorney for Applicants
Reg. No. 30,561